ArticleVeterinary research communications2024
Development and in vitro evaluation of a lignin-PLGA nanocarrier for florfenicol delivery.
Article in Veterinary research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of Lignin Incorporation on Properties of Polyester Films of Lignin-Grafted-PCL/PLGA/PLA Polymers as Packaging Materials.ACS omega · 2026Article
- Advantages and drawbacks of eco-friendly nano-delivery systems.Therapeutic delivery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Florfenicol (FF) is a widely used antimicrobial in veterinary medicine because of its broad antimicrobial activity, although it has certain limitations and raises concerns about the development of antimicrobial resistance genes. These limitations highlight the need to explore novel drug with controlled release systems to enhance the therapeutic efficacy of FF, while minimizing the potential for resistance development. This study introduces an innovative approach for the design, synthesis, and evaluation of lignin-poly(lactic-co-glycolic) acid (PLGA)-FF nanoparticles. By leveraging the properties of PLGA and lignin, this study aimed to augment the solubility, stability, and bioavailability of FF, thereby enabling dosage reduction and consequently diminishing the likelihood of resistance emergence and other limitations. Lignin-PLGA nanoparticles encapsulating FF were synthesized and characterized to assess their physicochemical properties, such as particle size, zeta potential, and drug loading efficiency. The release profile, antimicrobial efficacy, and cytotoxicity were evaluated. Comparative analyses with standard FF formulations were performed to ascertain the superior performance and potential benefits of the nanoparticle-based antimicrobials. Our findings indicate that the synthesized lignin-PLGA nanoparticles exhibited favorable drug delivery attributes, including a controlled and sustained release mechanism, significantly enhanced antimicrobial activity at reduced concentrations relative to free FF, with minimal cytotoxic effects. Importantly, the nanoparticle system inhibited bacterial biofilm formation, which is a key factor in the onset and spread of antimicrobial resistance. These findings underscore the potential of integrating biodegradable polymers with natural compounds to forge innovative pathways in drug delivery, addressing critical challenges in veterinary medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.